What are examples of fluoroquinolone antibiotics?

Fluoroquinolone Examples

Fluoroquinolones are categorized into generations based on their antimicrobial spectrum, with commonly used examples including ciprofloxacin, levofloxacin, moxifloxacin, and gatifloxacin.

Classification by Generation

First Generation

• Nalidixic acid was the prototype quinolone approved in 1964, with limited spectrum primarily against gram-negative urinary pathogens 1

Second Generation

• Ciprofloxacin - excellent gram-negative activity including Pseudomonas aeruginosa, but inadequate pneumococcal coverage 1
• Levofloxacin - enhanced gram-negative spectrum with improved gram-positive activity 1
• Norfloxacin - primarily used for urinary tract infections 1
• Ofloxacin - broad gram-negative coverage 1, 2

Third Generation (Respiratory Fluoroquinolones)

• Gemifloxacin - substantially increased activity against Streptococcus pneumoniae while retaining gram-negative activity 1
• Sparfloxacin - improved gram-positive activity but limited by phototoxicity concerns 1, 3

Fourth Generation

• Moxifloxacin - increased activity against anaerobes while maintaining gram-positive and gram-negative coverage 1, 4
• Gatifloxacin - excellent pneumococcal and anaerobic activity 1

Newer Agents

• Delafloxacin - enhanced activity with unique pharmacologic properties 5, 6

Key Antimicrobial Spectrum Distinctions

Gram-Negative Coverage

• Ciprofloxacin maintains the best activity against Pseudomonas aeruginosa among all fluoroquinolones 1, 3
• All fluoroquinolones demonstrate excellent activity against Haemophilus influenzae and Moraxella catarrhalis 1

Gram-Positive Coverage

• The newer fluoroquinolones (gatifloxacin, levofloxacin, moxifloxacin) have remarkable potency against gram-positive pathogens including S. pneumoniae, unlike ciprofloxacin 1
• Ciprofloxacin has an AUC-to-MIC ratio of only 10-20 against S. pneumoniae, well below the target of 25-30 1

Anaerobic Coverage

• Moxifloxacin, gatifloxacin, and trovafloxacin display improved activity against anaerobes including Bacteroides fragilis 1, 3, 7
• Ciprofloxacin and ofloxacin are inactive against most anaerobic bacteria 7

Critical Clinical Distinctions

Respiratory Tract Infections

• Ciprofloxacin is contraindicated for community-acquired pneumonia due to inadequate pneumococcal coverage and 20-25% treatment failure rates 8, 9
• Levofloxacin 750 mg daily, moxifloxacin, and gemifloxacin are the preferred fluoroquinolones for respiratory infections when this class is indicated 1, 8, 9

Pseudomonal Infections

• Ciprofloxacin remains the fluoroquinolone of choice for Pseudomonas aeruginosa infections, though resistance can develop rapidly during treatment 1

Enteric Infections

• Ciprofloxacin shows excellent activity against enteric pathogens including E. coli, Klebsiella, Salmonella, and Shigella species 9

Important Safety Considerations

All fluoroquinolones share class-wide adverse effects including:

• Achilles tendon rupture and tendinopathies, particularly in patients with renal dysfunction 1, 5, 4
• Peripheral neuropathy that may be permanent 5, 4
• Central nervous system effects including seizures 5, 4
• Worsening of myasthenia gravis 5, 4
• QTc prolongation (varies by agent) 1

Fluoroquinolones are not approved for routine use in children under 18 years due to arthrotoxicity concerns in juvenile animals, with limited exceptions 1